ArticleDiabetes & vascular disease research

US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.

Hridhay Karthikeyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.